Free delivery for orders over 69.99 euro.

Check order status

Become part of a community of book lovers from all over the world and get access to a whole bunch of benefits. Create an account for free

Free delivery for purchases over 69.99 €

DPD courier 5.99 € Bpost point 7.99 € Bpost 7.49 € DPD point 3.49 € GLS courier 4.49 €

Contact

How to shop

Help

My account

▸ Empty :-(

Free delivery for orders over 69.99 euro.

Activity-based proteomics

Name: Activity-based proteomics
Brand: Sudwestdeutscher Verlag Fur Hochschulschriften AG
SKU: 07148241
Price: 48.1 EUR
Availability: InStock
Author: Thomas Wiedl
ISBN: 9783838131375

Thomas Wiedl

Language

English

Book Paperback

Libristo code: 07148241

Publishers Sudwestdeutscher Verlag Fur Hochschulschriften AG, February 2012

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ra... Full description

Libristo code: 07148241

116 b

48.10 €

In stock at our supplier Shipping in 8-11 days

30-day return policy

Customers also purchased

Oscar Wilde's "Dorian Gray" in drei deutschen Übersetzungen Corinna Clauß

Paperback

50.02 €

Zulassigkeit der Nothwehr gegenuber beleidigenden AEusserungen, Leopold Bauke

Paperback

11.74 €

Šumava krásná a tajemná Martin Čihař

Hardback

15.79 €

Legislacion de marcas, patentes y diseño industrial RICARDO ALONSO

Hardback

67.55 €

Fosilie Michal Kašpárek

Paperback

9.21 €

Lung cancer is the leading cause of all cancer related deaths worldwide. The 5-year survival rate ranges from 80% in early stages to less than 5% in advanced disease. Non-small cell lung carcinoma (NSCLC) accounts for 80% of all lung malignancies, 40% of which are adenocarcinomas representing one of the most common lung cancer subtypes. Currently, prognosis is mostly determined based on the extension of disease at diagnosis. Thereby it has become evident that predicted and real outcomes can vary significantly, even for patients with the same stage of disease. Thus, novel biomarkers that refine prognosis with a reliable clinical significance are clearly needed. Therefore we aimed to implement an activity-based proteomics platform representing a powerful tool in the search for novel disease biomarkers.